PL354295A1 - Kompozycja farmaceutyczna - Google Patents

Kompozycja farmaceutyczna

Info

Publication number
PL354295A1
PL354295A1 PL00354295A PL35429500A PL354295A1 PL 354295 A1 PL354295 A1 PL 354295A1 PL 00354295 A PL00354295 A PL 00354295A PL 35429500 A PL35429500 A PL 35429500A PL 354295 A1 PL354295 A1 PL 354295A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
insulin sensitizer
sensitizer
insulin
pharmaceutical
Prior art date
Application number
PL00354295A
Other languages
English (en)
Inventor
Katsuichi Sudo
Yasuhiko Wada
Yasuo Sugiyama
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of PL354295A1 publication Critical patent/PL354295A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL00354295A 1999-09-03 2000-09-01 Kompozycja farmaceutyczna PL354295A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP25044399 1999-09-03
JP2000056021 2000-02-28
PCT/JP2000/005951 WO2001017513A2 (en) 1999-09-03 2000-09-01 Pharmaceutical composition comprising an insulin sensitizer

Publications (1)

Publication Number Publication Date
PL354295A1 true PL354295A1 (pl) 2004-01-12

Family

ID=26539777

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00354295A PL354295A1 (pl) 1999-09-03 2000-09-01 Kompozycja farmaceutyczna

Country Status (14)

Country Link
EP (1) EP1212090A2 (pl)
KR (1) KR20020063555A (pl)
CN (1) CN1372476A (pl)
AR (1) AR031674A1 (pl)
AU (1) AU6868000A (pl)
CA (1) CA2383946A1 (pl)
CO (1) CO5180632A1 (pl)
HK (1) HK1044711A1 (pl)
HU (1) HUP0203285A3 (pl)
NO (1) NO20021036L (pl)
PE (1) PE20010580A1 (pl)
PL (1) PL354295A1 (pl)
RU (1) RU2002108346A (pl)
WO (1) WO2001017513A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1695716A2 (en) * 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
KR20050010512A (ko) 2002-06-12 2005-01-27 스미또모 세이야꾸 가부시키가이샤 인돌, 인다졸 및 벤즈아졸류

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701152A (ko) * 1988-11-14 1992-08-11 로버트 에이. 아미테이지 당뇨병, 비반증 및 동맥경화증 치료제로 유용한 알파-아미노-인돌-3-세트산
ATE93138T1 (de) * 1990-02-09 1993-09-15 Upjohn Co Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
JP3100165B2 (ja) * 1994-11-29 2000-10-16 大日本製薬株式会社 インドール誘導体

Also Published As

Publication number Publication date
CA2383946A1 (en) 2001-03-15
CN1372476A (zh) 2002-10-02
AR031674A1 (es) 2003-10-01
PE20010580A1 (es) 2001-05-25
WO2001017513A3 (en) 2001-09-20
HK1044711A1 (zh) 2002-11-01
KR20020063555A (ko) 2002-08-03
NO20021036D0 (no) 2002-03-01
EP1212090A2 (en) 2002-06-12
RU2002108346A (ru) 2003-11-20
NO20021036L (no) 2002-04-26
HUP0203285A3 (en) 2003-02-28
AU6868000A (en) 2001-04-10
HUP0203285A2 (hu) 2003-01-28
CO5180632A1 (es) 2002-07-30
WO2001017513A2 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
PL351387A1 (en) Pharmaceutical composition
IL149224A0 (en) Hydrogen-driven drug dosage form
EG23858A (en) Drug combination
IL183972A0 (en) Pharmaceutical composition for modified release insulin sensitiser
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
ZA200000857B (en) Pharmaceutical composition.
IL145632A0 (en) Pharmaceutical compounds
GB9916434D0 (en) Pharmaceutical compounds
GB9914255D0 (en) Pharmaceutical compounds
GB9903784D0 (en) Pharmaceutical compounds
HUP0203285A3 (en) Pharmaceutical composition comprising an insulin sensitizer and its use
EP1051141A4 (en) INSULIN-CONTAINING AMYLINE AGONIST PHARMACEUTICAL COMPOSITIONS
GB9909154D0 (en) Pharmaceutical formulation
GB2373499B (en) Pharmaceutical compounds
GB9930160D0 (en) Drug delivery
GB9916210D0 (en) Pharmaceutical composition
GB9916413D0 (en) Pharmaceutical composition
HU9900587D0 (en) New pharmaceutical composition
GB9910671D0 (en) Improved pharmaceutical composition
GB9904304D0 (en) Drug delivery
GB9902593D0 (en) Drug combinations
GB9921064D0 (en) Drug combination
AUPQ386599A0 (en) Pharmaceutical composition
AUPP969899A0 (en) Pharmaceutical composition
GB9926437D0 (en) Pharmaceutical

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)